Understand the source comparison
Comparison: VIP vs Approved Fibromyalgia Medications
Mechanism VPAC receptor agonist; reduces neurogenic inflammation and cytokine release Calcium channel alpha-2-delta ligand; reduces excitatory neurotransmitter release SNRI; increases serotonin and norepinephrine in CNS SNRI; preferentially increases norepinep
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism
- VPAC receptor agonist; reduces neurogenic inflammation and cytokine release
- Calcium channel alpha-2-delta ligand; reduces excitatory neurotransmitter release
- SNRI; increases serotonin and norepinephrine in CNS
- SNRI; preferentially increases norepinephrine over serotonin
- VIP targets peripheral immune dysregulation. Fundamentally different pathway from central neuromodulators
- Route
- Intranasal or subcutaneous (research formulations)
- Oral capsule
- Oral tablet
- Delivery route is VIP's largest practical barrier. No oral bioavailability exists
- Half-Life
- 60–90 seconds (native peptide)
- 6.3 hours
- 12 hours
- 8 hours
- VIP requires modified analogs or sustained-release systems to achieve therapeutic stability
- Clinical Evidence
- Phase I safety data; Phase II efficacy pending
- FDA-approved 2007; multiple RCTs show 30–50% pain reduction in responders
- FDA-approved 2008; meta-analysis shows 1.5-point VAS reduction vs placebo
- FDA-approved 2009; reduces pain and fatigue scores by 20–25% in trials
- VIP is 15+ years behind approved therapies in clinical development. Comparable efficacy data doesn't exist yet
- Side Effect Profile
- Nasal congestion, vasodilation, transient hypotension (research reports)
- Weight gain, dizziness, peripheral oedema
- Nausea, dry mouth, insomnia, elevated blood pressure
- Nausea, headache, palpitations, hypertension
- VIP's side effects are route-dependent; pregabalin's weight gain and duloxetine's insomnia are consistent issues in long-term use
- Cost
- Not commercially available; research-grade VIP costs $180–$320 per mg
- $50–$150/month generic; $400+ brand
- $30–$80/month generic; $350+ brand
- $200–$400/month (limited generic availability)
- VIP's cost is prohibitive even in research settings. Clinical pricing would require scaled manufacturing